How does The Grand Slam Bundle work? What is its mechanism of action?

Reported Mechanisms — Component by Component Each section below summarizes the published mechanism of a single component. No combined mechanism is described in the literature, and none is asserted here. 1. GLP3-R / Retatrutide (30 mg) — Triple Receptor Agonism Retatrutide is described as engaging the GIP, GLP-1, and glucagon receptors with a single peptide sequence, distinguishing it from dual GIP/GLP-1 agonism and GLP-1-selective agonism.[1] Clinical pharmacology has been reported in phase 1b a

What are the research applications of The Grand Slam Bundle?

Research Applications (Component-Level) The published work behind each vial in this kit falls into the following areas. Every study listed used a single component or blend, not the bundle. Incretin and glucagon receptor pharmacology — retatrutide serves as the triple-agonist reference compound in comparisons against dual and selective agonists.[1][2] Metabolic research — phase 2 trials of the pharmaceutical formulation have been published in obesity and type 2 diabetes.[3][4] Matrix and fibrobla

How should The Grand Slam Bundle be stored?

Store each lyophilized vial at -20°C (long-term). Reconstituted: -80°C for extended storage, 2-8°C for short-term use. Keep the GLOW vial away from chelators (EDTA, carnosine, Vitamin C). Reconstitute and store each vial separately.

The Grand Slam Bundle: Safety Profile & Research Summary

Q: What is The Grand Slam Bundle?

Overview The Grand Slam Bundle groups three research materials, each characterized in a separate body of published work. It ships as three individual vials, two of which are themselves multi-peptide blends. GLP3-R is retatrutide (LY3437943). Coskun et al. published its discovery-to-clinical-proof-of-concept characterization as a triple glucagon, GIP, and GLP-1 receptor agonist; Urva et al. reported the phase 1b multiple-ascending-dose study; and phase 2 trials in obesity and type 2 diabetes have

22 Citas PubMedRevisado por EspecialistasCertificado GMPÚltima Revisión: julio de 2026

Research Summary (Component-Level)

No peer-reviewed study has evaluated this three-vial bundle as a unit. The table below lists representative findings for each component individually. Full per-component data and complete reference lists are on the dedicated GLP3-R, GLOW, and CJC (no DAC) / Ipamorelin pages.

Component	Representative Study	Reported Observation	Ref
GLP3-R	Coskun et al. (2022) — discovery	Characterized as a triple glucagon, GIP, and GLP-1 receptor agonist	[1]
GLOW / GHK-Cu	Maquart et al. (1988) — fibroblast culture	Reported stimulation of collagen synthesis by the tripeptide-copper complex	[7]
GLOW / BPC-157	Hsieh et al. (2017) — endothelial models	Pro-angiogenic activity associated with VEGFR2 activation	[8]
GLOW / TB-500	Philp et al. (2003) — rodent dermal wounds	Actin-binding-domain peptide reported to promote dermal wound repair	[11]
CJC (no DAC)	Jetté et al. (2005) — rats	GRF analog reported to activate the GRF receptor on the anterior pituitary	[14]
Ipamorelin	Raun et al. (1998) — characterization	Described as the first selective growth hormone secretagogue	[17]

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

In Vitro / Preclinical Disclaimer: The research findings described above were observed in laboratory (in vitro), animal model, and clinical research studies of individual compounds. Research-grade material sold here is for laboratory research use only. No claims are made regarding human therapeutic applications.

Educational Use Only: This content is provided for informational and educational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult qualified healthcare professionals for medical decisions.

Editorial Research Note

“Research Summary (Component-Level) No peer-reviewed study has evaluated this three-vial bundle as a unit.”

Pure U.S. Peptides Research Standards TeamInternal editorial group summarising published peptide research for an audience of qualified independent investigators.

Referencias

Preguntas de Investigación Relacionadas

→ What Is The Grand Slam Bundle?→ The Grand Slam Bundle: Mechanism of Action → The Grand Slam Bundle: Research Applications → The Grand Slam Bundle: Chemical Properties → Storing The Grand Slam Bundle: Best Practices

Related research

What is The Long Shot?What is The Radiant Bundle?What is GLOW?

Browse all research guides in the Peptide Research Library →

Desea la revisión completa de la investigación?

Ver Página Completa de Investigación de The Grand Slam Bundle→

SOLO PARA USO EN INVESTIGACIÓN

Este contenido se proporciona solo para fines educativos e informativos. Los productos se suministran exclusivamente para estudios in vitro y no son medicamentos, fármacos ni suplementos. No están aprobados por la FDA para prevenir, tratar o curar ninguna condición.